ArriVent Appoints Kristine Peterson to its Board of Directors
April 22, 2024 16:05 ET
|
ArriVent BioPharma, Inc.
NEWTON SQUARE, Pa., April 22, 2024 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc., a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical...
ArriVent BioPharma Reports Full Year 2023 Financial Results
March 28, 2024 16:05 ET
|
ArriVent BioPharma, Inc.
Company progresses the development of furmonertinib with a data readout planned for 2024Furmonertinib granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration Completed $201...
ArriVent Announces Pricing of Upsized Initial Public Offering
January 25, 2024 21:30 ET
|
Arrivent Biopharma, Inc.
NEWTOWN SQUARE, Pa., Jan. 25, 2024 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (“ArriVent”) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative...
ArriVent Appoints Winston Kung as Chief Financial Officer and Treasurer
January 05, 2024 16:15 ET
|
Arrivent Biopharma, Inc.
NEWTON SQUARE, Pa., Jan. 05, 2024 (GLOBE NEWSWIRE) -- ArriVent Biopharma, Inc., a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical...
ArriVent Receives FDA Breakthrough Therapy Designation for Furmonertinib for First-Line Treatment of Advanced or Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
October 30, 2023 06:00 ET
|
Arrivent Biopharma, Inc.
NEWTOWN SQUARE, Pa., Oct. 30, 2023 (GLOBE NEWSWIRE) -- ArriVent Biopharma, Inc., a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical...
ArriVent Appoints Chris Nolet to its Board of Directors
September 20, 2023 16:05 ET
|
Arrivent Biopharma, Inc.
NEWTOWN SQUARE, Pa., Sept. 20, 2023 (GLOBE NEWSWIRE) -- ArriVent Biopharma, Inc., a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical...
Allist and ArriVent Announce Interim Results from Ongoing Phase 1b Trial with Furmonertinib at the 2023 World Conference on Lung Cancer
September 10, 2023 01:30 ET
|
Arrivent Biopharma, Inc.
SHANGHAI, China, Sept. 10, 2023 (GLOBE NEWSWIRE) -- Allist Pharmaceuticals Co., Ltd. (“Allist”) and ArriVent Biopharma, Inc. (“ArriVent”) together announced that interim results from the Phase Ib,...